MVP
TCRT icon

Miller Value Partners’s Alaunos Therapeutics TCRT Stock Holding History

Miller Value Partners’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-68,785
Closed -$27.2M – 133
2021
Q2 		$27.2M Sell
68,785
-10,113
-13% -$4.72M 0.65% 44
2021
Q1 		$42.6M Sell
78,898
-4,210
-5% -$2.62M 1.1% 39
2020
Q4 		$31.4M Buy
83,108
+537
+0.7% +$214K 0.96% 39
2020
Q3 		$31.2M Sell
82,571
-1,561
-2% -$690K 1.12% 39
2020
Q2 		$41.4M Sell
84,132
-1,582
-2% -$705K 1.84% 24
2020
Q1 		$31.5M Buy
85,714
+819
+1% +$424K 2.03% 25
2019
Q4 		$60.1M Sell
84,895
-1,659
-2% -$1.14M 2.13% 25
2019
Q3 		$55.6M Buy
86,554
+24,960
+41% +$19.8M 2.23% 22
2019
Q2 		$53.9M Hold
61,594
– – 2.05% 24
2019
Q1 		$35.6M Sell
61,594
-171
-0.3% -$71.5K 1.41% 32
2018
Q4 		$16.6M Buy
61,765
+29,648
+92% +$11.7M 0.75% 35
2018
Q3 		$15.4M Sell
32,117
-661
-2% -$283K 0.5% 40
2018
Q2 		$14.8M Sell
32,778
-808
-2% -$512K 0.55% 38
2018
Q1 		$19.7M Sell
33,586
-309
-0.9% -$193K 0.82% 36
2017
Q4 		$21M Buy
33,895
+1,506
+5% +$1.08M 0.9% 33
2017
Q3 		$29.8M Sell
32,389
-454
-1% -$403K 1.28% 28
2017
Q2 		$30.6M Buy
32,843
+8
+0% +$7.84K 1.24% 25
2017
Q1 		$31.2M Buy
32,835
+164
+0.5% +$153K 1.37% 25
2016
Q4 		$26.2M Sell
32,671
-702
-2% -$633K 1.15% 31
2016
Q3 		$28.2M Hold
33,373
– – 1.15% 30
2016
Q2 		$27.5M Sell
33,373
-3,084
-8% -$3.36M 1.23% 27
2016
Q1 		$40.6M Buy
36,457
+4,498
+14% +$4.6M 1.56% 28
2015
Q4 		$39.8M Buy
31,959
+5,602
+21% +$9.27M 1.07% 33
2015
Q3 		$35.6M Buy
26,357
+3,173
+14% +$5.24M 1.02% 33
2015
Q2 		$41.7M Buy
23,184
+3,184
+16% +$4.94M 1.45% 30
2015
Q1 		$32.3M Buy
+20,000
New +$29.6M 1.13% 37

Other funds holding TCRT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Miller Value Partners's TCRT Position: Q3 2021 in Review

Miller Value Partners sold out of Alaunos Therapeutics (TCRT) in Q3 2021, closing a stake of 68,785 shares — an estimated $27.2M sold.

Miller Value Partners first reported a position in TCRT in Q1 2015 and held it in 26 quarters. The position peaked at $60.1M in Q4 2019. 162 funds tracked by Wall St. Rank hold TCRT as of Q3 2021.

  • Miller Value Partners reported no remaining Alaunos Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Miller Value Partners sold 68,785 Alaunos Therapeutics shares in Q3 2021, an estimated $27.2M.
  • Miller Value Partners first reported a position in Alaunos Therapeutics in Q1 2015 and held it in 26 quarters.
  • Miller Value Partners's Alaunos Therapeutics position peaked at $60.1M in Q4 2019.
  • 162 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q3 2021.

Based on Miller Value Partners's 13F filing for Q3 2021, filed 15 Nov 2021.